YWYunzhi Wang

Yunzhi Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yunzhi Wang has a total of 159 co-authors. Here are the top co-authors by number of shared publications:

  • Chen Ding

    State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Institutes of Biomedical Sciences, Human Phenome Institute, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

    16 shared publications
  • Jinwen Feng

    Clinical Research Center for Cell-based Immunotherapy of Shanghai Pudong Hospital, Fudan University Pudong Medical Center, State Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Human Phenome Institute, Department of Urology, Fudan University Shanghai Cancer Center, Center for Cell and Gene Therapy, Fudan University, Shanghai, China

    9 shared publications
  • Zhaoyu Qin

    State Key Laboratory of Genetics and Development of Complex Phenotypes, School of Life Sciences, Institutes of Biomedical Sciences, Human Phenome Institute, Department of Pathology, Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200433, China

    8 shared publications
  • Jiajun Zhu

    7 shared publications
  • Peng Ran

    State Key Laboratory of Genetic Engineering and Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Institutes of Biomedical Sciences, Human Phenome Institute, Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

    7 shared publications
  • Yingyong Hou

    Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China

    7 shared publications

Latest Publications

  • Retraction
    Open Access

    Retraction Note: Proteomic characterization identifies clinically relevant subgroups of soft tissue sarcoma

    by Shaoshuai Tang, Yunzhi Wang, Rongkui Luo, Rundong Fang, Yufeng Liu, Hang Xiang, Peng Ran, Yexin Tong, Mingjun Sun, Subei Tan, et al.

  • Retraction
    Open Access

    Retraction Note: Proteogenomics of diffuse gliomas reveal molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms

    by Yunzhi Wang, Rongkui Luo, Xuan Zhang, Hang Xiang, Bing Yang, Jinwen Feng, Mengjie Deng, Peng Ran, Akesu Sujie, Fan Zhang, et al.

  • Open Access

    Plasma proteomic profiling reveals distinct molecular signatures associated with coronary collateral circulation in patients with chronic total occlusion

    by Yi-Ning Yang, Jun-Yi Luo, Peng Ran, Fen Liu, Ya-Jing Qiu, Bin-Bin Fang, Yunzhi Wang, Sha Tian, Xiao-Mei Li, Chen Ding

    Background: Coronary collateral circulation (CCC) plays a critical cardioprotective role in mitigating myocardial ischemia through its dynamic compensatory capacity. Clinical evidence has demonstrated that well-CCC development preserves relatively cardiac functional stability even in the presence of complete native coronary artery occlusion. However, the molecular mechanisms underlying CCC formation remain poorly understood, and there is a lack of clinically actionable non-invasive biomarkers for classifying CCC status in patients with chronic total occlusion (CTO). Methods: Using a data-independent acquisition quantitative proteomic approach, this study comprehensively analyzed 235 plasma samples from two independent CTO cohorts. Collateral filling from the contralateral vessel was categorized into four grades according to the Rentrop classification criteria (Grade 0 to 3). Results: Proteome profiling revealed enrichment of protein degradation and ion transport pathways in patients with good-CCC CTO, whereas immune responses and vascular remodeling pathways predominated in patients with bad-CCC. Using candidate plasma protein biomarkers (SOD1, UFD1, DDX5, MIA3, TOM1, and LMAN2) in conjunction with clinical data, CCC classifiers were developed that demonstrated high predictive accuracy, achieving an area under the curve of 0.91 in the discovery cohort. The robustness and generalizability of the model were further confirmed in an independent validation cohort, with an area under the curve (AUC) of 0.82. ELISA analysis revealed that the candidate plasma proteins effectively discriminated CCC status in patients with CTO, achieving an AUC of 0.76 (95% CI, 0.73–0.77) and an area under the precision-recall curve (AUPRC) of 0.79 (95% CI, 0.77–0.81). Additionally, a risk prediction model for main adverse cardiovascular and cerebrovascular events (MACCEs) was constructed based on a panel of nine plasma proteins, providing a potential tool for the early identification of patients at high-risk of CTO. Conclusion: Machine learning models based on plasma proteomic profiles outperformed existing clinical models in predicting CCC status. The developed risk prediction model for MACCEs provides a non-invasive approach for early stratification of patients at high risk of CTO.

  • A “Depolarization‐Activation” Strategy Targeting Microglia: Cuproptosis‐Mediated Immune Re‐Sensitization Nanoplatform in Glioma Therapy

    by Yi Liu, Yue Wu, Ran Cao, Jiting Zhang, Chen Yuan, Qiang Xie, Jiamin Hu, George Takura Tabengwa, Zijiang Yang, Yunzhi Wang, et al.

    Despite the necessity of repolarizing tumor‐associated microglia/macrophages (TAMs) to reverse the highly immunosuppressive microenvironment in gliomas, clinical translation is hindered by tumor heterogeneity and therapeutic dose safety concerns. Here, we develop a “depolarization‐activation” strategy: cuproptosis depolarizes TAMs to an “erased” stage regardless of tumor subtypes, leading to a universally enhanced susceptibility to immunoactivating agents. The cuproptosis inducer Elesclomol‐Cu (EsCu) and activation agent MK8931 are encapsulated into one nanoplatform with glioma targeting polymers (EsCu/MK@M‐P). Sub‐lethal level cuproptosis treatment significantly downregulates all polarization markers in TAMs, depolarizing TAMs to an immature state. MK8931 at a low dosage subsequently activates TAMs toward a tumor‐killing phenotype, achieving immunotherapeutic efficacy on glioma cells. In vitro and in vivo models, multi‐omics analysis, and patient‐derived organoids validate broad‐spectrum anti‐glioma potency and improved biosafety. Therefore, the “depolarization‐activation” strategy reveals that sub‐lethal hits erase the immunosuppressive property of tumor microenvironment for following immunoactivation, promisingly innovating current cancer immunotherapy strategies.


  • Open Access

    Integrated plasma and vegetation proteomic characterization of infective endocarditis for early diagnosis and treatment

    by Shiman He, Xuejiao Hu, Jiajun Zhu, Weiteng Wang, Chi Ma, Peng Ran, Oudi Chen, Fanyu Chen, Hongkun Qing, Jianhong Ma, et al.

    Infective endocarditis, a life-threatening condition, poses challenges for early diagnosis and personalized treatment due to insufficient biomarkers and limited understanding of its pathophysiology. Here, we performed proteomic profiling of plasma and vegetation samples from 238 patients with infective endocarditis and 100 controls, with validation in two external plasma cohorts (n = 328). We developed machine learning-based diagnostic and prognostic models for infective endocarditis, with area under the curve values of 0.98 and 0.87, respectively. Leucine-rich alpha-2-glycoprotein 1 and NADH:ubiquinone oxidoreductase subunit B4 are potential biomarkers associated with infection severity. Pathologically, protein networks characterized by glycometabolism, amino acid metabolism, and adhesion are linked to adverse events. Liver dysfunction may exacerbate the condition in patients with severe heart failure. Neutrophil extracellular traps emerge as promising therapeutic targets in Streptococcus or Staphylococcus aureus infections. Our findings provide insights into biomarker discovery and pathophysiological mechanisms in infective endocarditis, advancing early diagnosis and personalized medicine.


  • Open Access

    Proteogenomic characterization of skull-base chordoma

    by Qilin Zhang, Ziyan Xu, Rui Han, Yunzhi Wang, Zhen Ye, Jiajun Zhu, Yixin Cai, Fan Zhang, Jiangyan Zhao, Boyuan Yao, et al.

    Skull-base chordoma is a rare, aggressive bone cancer with a high recurrence rate. Despite advances in genomic studies, its molecular characteristics and effective therapies remain unknown. Here, we conduct integrative genomics, transcriptomics, proteomics, and phosphoproteomics analyses of 187 skull-base chordoma tumors. In our study, chromosome instability is identified as a prognostic predictor and potential therapeutic target. Multi-omics data reveals downstream effects of chromosome instability, with RPRD1B as a putative target for radiotherapy-resistant patients. Chromosome 1q gain, associated with chromosome instability and upregulated mitochondrial functions, lead to poorer clinical outcomes. Immune subtyping identify an immune cold subtype linked to chromosome 9p/10q loss and immune evasion. Proteomics-based classification reveals subtypes (P-II and P-III) with high chromosome instability and immune cold features, with P-II tumors showing increased invasiveness. These findings, confirmed in 17 paired samples, provide insights into the biology and treatment of skull-base chordoma.


  • From Hit to Lead: Discovery of First-In-Class Furanone Glycoside D228 Derived from Chimonanthus salicifolius for the Treatment of Inflammatory Bowel Disease

    by Mei-Lin Tang, Xiao-Yu Xiong, Heyanhao Zhang, Yun-Zhi Wang, Rong-Qian Cheng, Jianping Zuo, Lin Jin, Ze-Min Lin, Jun Chang

    TNFα and related inflammatory factor antibody drugs have been orchestrated for the treatment of inflammatory bowel disease (IBD). However, antibody drugs elicited inevitable disadvantages and small molecule drugs are in an urgent need. Herein, we described the discovery, design, synthesis, and SAR studies from furanone glycoside compound Phoenicein (hit) isolated from Chimonanthus salicifolius to D228 (lead). Remarkably, D228 exhibited good inhibitory activity on B and T lymphocyte and excellent anti-IBD efficacy in vivo. Mechanistically, D228 alleviated the inflammation response by downregulating the MyD88/TRAF6/p38 signaling. Importantly, the relationship of D228, Phoenicein, and their aglycone 7a was deduced: D228 could be considered as a prodrug and metabolized to intermediate Phoenicein. In turn, Phoenicein released their shared active aglycone 7a. Additionally, D228 demonstrated good and balanced profiles of safety and efficacy both in vitro and in vivo. These results suggested that D228 could be used as an ideal lead and potentially utilized for IBD chemotherapy.


  • Proteogenomic Analysis Identifies a Causal Association between Plasma Apolipoprotein B Levels and Liver Cancer Risk

    by Zhenqiu Liu, Huangbo Yuan, Yunzhi Wang, Kai Li, Chen Suo, Li Jin, Chen Ding, Xingdong Chen

    Liver oncogenesis is accompanied by discernible protein changes in the bloodstream. By employing plasma proteomic profiling, we can delve into the molecular mechanisms of liver cancer and pinpoint potential biomarkers. In this nested case-control study, we applied liquid chromatography-tandem mass spectrometry for proteome profiling in baseline plasma samples. Differential protein expression was determined and was subjected to functional enrichment, network, and Mendelian randomization (MR) analyses. We identified 193 proteins with notable differential levels between the groups. Of these proteins, MR analysis offered a compelling negative association between apolipoprotein B (APOB) and liver cancer. This association was further corroborated in the UK Biobank cohort: genetically predicted APOB levels were associated with a 31% (95% CI 19-42%) decreased risk of liver cancer; and phenotypic analysis indicated an 11% (95% CI 8-14%) decreased liver cancer risk for every 0.1 g/L increase of circulating APOB levels. Multivariable MR analysis suggested that the hepatic fat content might fully mediate the APOB-liver cancer connection. In summary, we identified some plasma proteins, particularly APOB, as potential biomarkers of liver cancer. Our findings underscore the intricate link between lipid metabolism and liver cancer, offering hints for targeted prophylactic strategies and early detection.


  • Retracted
    Open Access

    Proteomic characterization identifies clinically relevant subgroups of soft tissue sarcoma

    by Shaoshuai Tang, Yunzhi Wang, Rongkui Luo, Rundong Fang, Yufeng Liu, Hang Xiang, Peng Ran, Yexin Tong, Mingjun Sun, Subei Tan, et al.

    Soft tissue sarcoma is a broad family of mesenchymal malignancies exhibiting remarkable histological diversity. We portray the proteomic landscape of 272 soft tissue sarcomas representing 12 major subtypes. Hierarchical classification finds the similarity of proteomic features between angiosarcoma and epithelial sarcoma, and elevated expression of SHC1 in AS and ES is correlated with poor prognosis. Moreover, proteomic clustering classifies patients of soft tissue sarcoma into 3 proteomic clusters with diverse driven pathways and clinical outcomes. In the proteomic cluster featured with the high cell proliferation rate, APEX1 and NPM1 are found to promote cell proliferation and drive the progression of cancer cells. The classification based on immune signatures defines three immune subtypes with distinctive tumor microenvironments. Further analysis illustrates the potential association between immune evasion markers (PD-L1 and CD80) and tumor metastasis in soft tissue sarcoma. Overall, this analysis uncovers sarcoma-type-specific changes in proteins, providing insights about relationships of soft tissue sarcoma.


  • Open Access

    Longitudinal plasma proteome profiling reveals the diversity of biomarkers for diagnosis and cetuximab therapy response of colorectal cancer

    by Yan Li, Bing Wang, Wentao Yang, Fahan Ma, Jianling Zou, Kai Li, Subei Tan, Jinwen Feng, Yunzhi Wang, Zhaoyu Qin, et al.

    Cetuximab therapy is the major treatment for colorectal cancer (CRC), but drug resistance limits its effectiveness. Here, we perform longitudinal and deep proteomic profiling of 641 plasma samples originated from 147 CRC patients (CRCs) undergoing cetuximab therapy with multi-course treatment, and 90 healthy controls (HCs). COL12A1, THBS2, S100A8, and S100A9 are screened as potential proteins to distinguish CRCs from HCs both in plasma and tissue validation cohorts. We identify the potential biomarkers (RRAS2, MMP8, FBLN1, RPTOR, and IMPDH2) for the initial response prediction. In a longitudinal setting, we identify two clusters with distinct fluctuations and construct the model with high accuracy to predict the longitudinal response, further validated in the independent cohort. This study reveals the heterogeneity of different biomarkers for tumor diagnosis, the initial and longitudinal response prediction respectively in the first course and multi-course cetuximab treatment, may ultimately be useful in monitoring and intervention strategies for CRC.